Friday, 13 December 2013: 11:35 - 11:55
Great Lakes Grand Ballroom East (Westin - Michigan Avenue)
Sarbjit Saini, MD FAAAAI
,
Medicine, Johns Hopkins University, Baltimore, MD
Learning Objectives:
Classify the benefits of the anti-IgE monoclonal antibody (omalizumab) in inducing and maintaining long-term remission for patients with severe chronic urticaria.
Recognize the role of the Anti-IgE monoclonal antibody (omalizumab) in inducing and maintaining long term remission for patients with sever chronic urticaria.
Classify the benefits of the anti-IgE monoclonal antibody (omalizumab) in inducing and maintaining long-term remission for patients with severe chronic urticaria.
Recognize the role of the Anti-IgE monoclonal antibody (omalizumab) in inducing and maintaining long term remission for patients with sever chronic urticaria.